PT  - JOURNAL ARTICLE
AU  - Vera Loizzi
AU  - Francesca Arezzo
AU  - Isabella Romagno
AU  - Miriam Dellino
AU  - Erica Silvestris
AU  - Anila Kardhashi
AU  - Gerardo Cazzato
AU  - Leonardo Resta
AU  - Francesco Legge
AU  - Luca Damiani
AU  - Iole Natalicchio
AU  - Nicoletta Resta
AU  - Ettore Cicinelli
AU  - Gennaro Cormio
TI  - 2022-RA-822-ESGO Risk reducing surgery in ovarian cancer
AID  - 10.1136/ijgc-2022-ESGO.569
DP  - 2022 Oct 01
TA  - International Journal of Gynecologic Cancer
PG  - A266--A267
VI  - 32
IP  - Suppl 2
4099  - http://ijgc.bmj.com/content/32/Suppl_2/A266.2.short
4100  - http://ijgc.bmj.com/content/32/Suppl_2/A266.2.full
SO  - Int J Gynecol Cancer2022 Oct 01; 32
AB  - Introduction/Background The study evaluated the risk of ovarian cancer in women with BRCA 1–2 mutations. BRCA 1–2 are tumor-suppressor genes involved in DNA homologous recombination and ovarian cancer developmentMethodology From 2016 to may 2022, all risk reducing surgery (RRSO) which included salpingo-oophorectomy was performed in all patients carrying BRCA1 and BRCA 2 mutation.Results We collected 172 women. The median age of BRCA 1 mutated patients was 51 aged (range 30–73 years), whereas the median age of BRCA 2 mutated patients was 53 (range 36–70). One hundred and three patients had previous history of breast cancer. Among the 172, 145 (85%) underwent risk reducing salpingo-oohorectomy (RRSO) though a laparoscopic minimally invasive approach. 12 (7%) underwent laparoscopic RRSO and contextual hysterectomy, 3 (2%) underwent RRSO through a laparotomic approach and 10 (6%) laparotomic RRSO and hysterectomy. During 8 (5%) laparoscopic RRSO, prophylactic bilateral mastectomy was also performed. Early and late complications occurred in 3 patients (2%). Four patients (2%) were found to have occult serous tubal intraepithelial carcinoma (STIC) and nine patients (5%) occult cancer.Conclusion RRSO is a safe and feasible procedure in BRCA 1–2 mutation carriers. The procedure is effective for genetic prevention of ovarian cancer.